Thomas Georgas: HIT Requires More Than a Platelet Count
Thomas Georgas, Education Specialist at Dorset Council and BCP Council, shared Sysmex Europe’s post on LinkedIn, adding:
”An interesting paradox.
The ‘bleeding-number’ (platelet fall) can distract, while the real emergency is an immune-driven surge in thrombin generation and thrombosis risk.
From an ISO 15189 perspective, it also subtly points to why HIT needs a tightly governed diagnostic pathway—clear referral criteria, defined sample requirements, rapid turnaround, and assay-specific interpretive support—so clinicians can act on probability and results without delay or misinterpretation.”
Sysmex Europe shared a post on LinkedIn:
”What happens when the drug meant to prevent clots starts causing them?
Heparin-induced thrombocytopenia (HIT) is a rare yet dangerous immune reaction in which antibodies activate platelets, leading to a sharp increase in thrombosis risk.
Understanding these interactions at the molecular level is the first step towards recognising HIT early, when it matters most.”
Proceed to the video attached to the post.
Stay updated with Hemostasis Today.
-
Oct 11, 2026, 15:15Thalassaemia International Federation Joins ASCAT 2026 to Advance Sickle Cell and Thalassaemia Care
-
Oct 11, 2026, 15:14Challenges and Perspectives on Gene Therapy in Hemophilia A – Seminars in Thrombosis and Hemostasis
-
Oct 11, 2026, 15:07Neysa Rahardjo: Platelet Estimation Pitfalls and Discrepancy Resolution
-
Oct 11, 2026, 15:05Lance Trewhella: Reflections from the ASCLS Region V Fall Symposium
-
Oct 11, 2026, 15:04The Anti-Inflammatory Rationale for GLP-1 Agonists in Hemophilia – CRH French Reference Center for Hemophilia Lyon
-
Oct 11, 2026, 15:00Donja W.: Blood Shortages Aren’t Just Statistics
-
Oct 11, 2026, 14:54Archil Jaliashvili: NHSBT Highlights Persistent Gaps in Matched Blood for Sickle Cell Patients
-
Oct 11, 2026, 14:46Sebastien Lobet: Physiotherapy and Joint Health Across the Spectrum of Bleeding Disorders
-
Oct 11, 2026, 14:38Vandana Puri: Heme Next Showcases the Future of Hematology